Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-05
2011-04-05
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S324000, C548S548000
Reexamination Certificate
active
07919455
ABSTRACT:
The present invention relates to a peptide labelled with fluorine-18 for the specific recognition of lipid vectors. The peptide of the invention comprises the following peptide sequence (PI):(I)J1-J2-J3-J4-J5-J6-Z7-U8-J9-J10-U11-Arg-J13-J14-U15-Lys-Gly-X18-Gly-Thr-J21-Glu-J23-J24-U25-J26-J27-J28-U29-J30-J31-Arg-J33-J34-J35-J36-B37-J38-J39-U40-J41-J42-J43-U44-J45-J46-J47-J48-J49-Arg-J51-U52-J53-J54-Asp-U56-Lys-Ser-Z59-Leu-J61-J62-J63-J64-Z65-J66-J67-U68-J69-J70-J71-U72-J73-J74-J75in which the amino acids J are chosen independently of each other from natural amino acids, or derivatives thereof, in such a manner that at least 50% of them are polar residues chosen from Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Lys, Orn, Pro, Ser, Thr and Tyr, the amino acids U are chosen from Ala, Cys, Gly, Ile, Leu, Met, Phe, Trp, Tyr and Val, the amino acid X18is chosen independently of the other amino acids of the sequence from Ala, Asn, Cys, Gln, Gly, His, Ile, Leu, Met, Phe, Ser, Thr, Trp, Tyr and Val, the amino acid B37is chosen independently of the other amino acids of the sequence from Arg, Ala, Cys, Gly, Ile, Leu, Met, Phe, Trp, Tyr and Val, the amino acid Z7is chosen independently of the other amino acids from Asp and Glu, the amino acids Z59and Z65are chosen independently from Glu, Asp, Lys and Arg, the superscripts of the residues J, Z, U, X and B representing the positions of these amino acids in the said sequence.
REFERENCES:
patent: 4735792 (1988-04-01), Srivastava
patent: 0 293 567 (1988-12-01), None
patent: 92/19279 (1992-11-01), None
patent: WO 99/11590 (1999-03-01), None
patent: 00/20453 (2000-04-01), None
Zijlstra et al., “Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET”, Applied Radiation and Isotopes, vol. 58, No. 2, pp. 201-207. Feb. 2003.
Montaville, Pierre et al. “A New Consensus Sequence for Phosphatidylserine Recognition by Annexins”, Journal of Biological Chemistry, vol. 277, No. 27, pp. 24684-24693, XP002268388 2002.
Shiue, C.-Y. et al. “Synthesis of 18F-labelled N-(p-[18F]fluorophenyl)maleimide and Its Derivatives for Labelling Monoclonal Antibody with 18F”, Journal of Labelled Compounds and Radiopharmaceuticals, vol. 26, pp. 287-289, XP002091356 1989.
Burgess, Kevin et al. “Solid-Phase Syntheses of Guanidines”, Wiley-Interscience, pp. v-ix 2000.
Fliss, Henry et al. “Apoptosis in Ischemic and Reperfused Rat Myocardium”, Circ. Res., vol. 79, pp. 949-956 1996.
Cordier-Ochsenbein, Francoise et al. “Exploring the Folding Pathways of Annexin I, a Multidomain Protein. II. Hierarchy in Domain Folding Propensities may Govern the Folding Process”, J. Mol. Biol., vol. 279, pp. 1177-1185 1998.
Dolle Frederic
Ochsenbein Francoise
Sanson Alain
Commissariat a l''Energie Atomique
Gupta Anish
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Universite Pierre Et Marie Curie (Paris VI)
LandOfFree
Marked peptides having affinity for a phospholipid and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Marked peptides having affinity for a phospholipid and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Marked peptides having affinity for a phospholipid and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687600